Search Tag: wegovy

2024 24 Jun

  Semaglutide has demonstrated significant symptom improvement in both men and women suffering from a common type of heart failure with limited treatment options. Research presented at the American Diabetes Association’s 2024 Scientific Sessions and published in the Journal of the American College of Cardiology reveals that women achieved greater...Read more

2024 21 Jun

  The World Health Organization (WHO) has issued a global alert about fake versions of Ozempic, a drug that has gained significant popularity for weight loss. Although Ozempic is primarily prescribed for type 2 diabetes, it is sometimes referred to as a "skinny jab" due to its weight-loss effects. The WHO has warned that the fake versions of Ozempic...Read more

2024 22 May

  A recent analysis shows that semaglutide, a prescription drug (brand names Wegovy and Ozempic), may reduce the risk of heart attacks and strokes in individuals, regardless of their weight loss success.   Prof John Deanfield from the UCL Institute of Cardiovascular Disease led the study. Researchers analysed data from the Semaglutide and...Read more

2023 05 Sep

Novo Nordisk, the Danish pharmaceutical giant behind the weight-loss medication Wegovy (active ingredient - semaglutide), has become Europe's most valuable company, dethroning the French luxury conglomerate LVMH.   Following the successful launch of Wegovy in the U.K., the company's shares saw a significant uptick in value. As trading closed...Read more